Arrhythmogenic Right Ventricular Dysplasia Treatment Market

Introduction

Arrhythmogenic right ventricular dysplasia is a rare kind of cardiomyopathy disease in which the right ventricle (RV) of the heart muscle (myocardium) is replaced by fat and fibrous scar tissue. In some cases, heart transplantation is being performed in order to treat the disease. In this disease, the right ventricle extends and contracts owing to which the capability of the heart to pump blood depletes.

Patients with arrhythmogenic right ventricular dysplasia often have arrhythmias (abnormal heart rhythms), which can increase the risk of sudden cardiac arrest or may lead to death. Arrhythmogenic right ventricular dysplasia can boost the gamble for sudden cardiac arrest (SCA); so an implantable cardioverter defibrillator (ICD) can be used to reduce this risk. Management of the disease may include surgeries, medications, non-surgical procedures, e.g., septal ablation and radiofrequency ablation.

Arrhythmogenic Right Ventricular Dysplasia Treatment Market: Drivers and Restraints

By epidemiology, according to the Centers for Diseases Control and Prevention, arrhythmogenic right ventricular dysplasia has a prevalence of 1 in 2500 to 1 in 5000 population. The increase in the prevalence of the disease is expected to drive the growth of the arrhythmogenic right ventricular dysplasia treatment market. Increasing prevalence of congenital heart diseases is also a major factor due to which cardiomyopathy diagnostic is high in demand in the recent years.

Many manufacturers are focusing on research and development of qualitative cardiomyopathy diagnostics procedures. The high demand for innovative diagnostics procedures is projected to drive the growth of the market for arrhythmogenic right ventricular dysplasia treatment over the forecast period.

Arrhythmogenic Right Ventricular Dysplasia Treatment Market: Overview

The global arrhythmogenic right ventricular dysplasia treatment market is expected to grow at a high CAGR due to the increasing adoption and demand for arrhythmogenic right ventricular dysplasia treatment procedures. Based on the treatment, it is observed that surgical procedures are being followed most of the time.

On the basis of end users, the hospital segment is expected to hold maximum revenue share in the global arrhythmogenic right ventricular dysplasia treatment market over the forecast period. One of the most common use of arrhythmogenic right ventricular dysplasia treatment is to control the other associated diseases such as Fabry disease, Danon disease, Noonan syndrome, Alagille syndrome and Holt-Oram syndrome, and mitochondrial myopathy, among others.

Arrhythmogenic Right Ventricular Dysplasia Treatment Market: Key Players

Examples of some of the key players operating in the global arrhythmogenic right ventricular dysplasia treatment market are CENTOGENE AG, Ambry Genetics, GeneDx, Illumina, Inc. Asper Biogene, Cohesion Phenomics, Blueprint Genetics Oy, Aetna Inc. Invitae Corporation, among others. It is analyzed that the leading market players are majorly focusing on increasing their market presence by adopting various strategic activities such as acquisitions, agreements, collaborations, and mergers, among others.

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, and inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators, and governing factors, along with market attractiveness as per segment. The report also maps the qualitative impact of various market factors on market segments and geographies.

The report covers exhaustive analysis on:

• Market Segments
• Market Dynamics
• Market Size
• Supply & Demand
• Current Trends/Issues/Challenges
• Competition & Companies Involved
• Technology
• Value Chain

Regional analysis includes

• North America (U.S., Canada)
• Latin America (Mexico, Brazil)
• Western Europe (Germany, Italy, U.K, Spain, France, Nordic Countries, BENELUX)
• Eastern Europe (Russia, Poland, Rest Of Eastern Europe)
• Asia Pacific Excluding Japan (China, India, Australia & New Zealand)
• Japan
• Middle East and Africa (GCC, S. Africa, Rest of MEA)

Report Highlights:

• Detailed overview of parent market
• Changing market dynamics in the industry
• In-depth market segmentation
• Historical, current, and projected market size in terms of volume and value
• Recent industry trends and developments
• Competitive landscape
• Strategies of key players and products offered
• Potential and niche segments, geographical regions exhibiting promising growth
• A neutral perspective on market performance
• Must-have information for market players to sustain and enhance their market footprint

Arrhythmogenic Right Ventricular Dysplasia Treatment Market: Segmentation

Generally, the global arrhythmogenic right ventricular dysplasia treatment market can be segmented on the basis of treatment, end user and geography.

Based on treatment, the global arrhythmogenic right ventricular dysplasia treatment market is segmented as:

• Surgical :
  • Implantable cardioverter-defibrillator (ICD). 
  • Ventricular assist device (VAD
  • Pacemaker
  • Septal myectomy
  • Heart transplant. 
  • Others
• Non-surgical:
  • Septal ablation
  • Radiofrequency ablation

Based on end users, the global arrhythmogenic right ventricular dysplasia treatment market is segmented as:

• Hospitals
• Clinics
• Diagnostics Imaging Center
• Ambulatory Care Center
• Ambulatory Surgery Center
• Others